. Author manuscript; available in PMC: 2023 Jul 1.

Published in final edited form as: J Natl Compr Canc Netw. 2022 Jul;20(7):783–791.e1. doi: 10.6004/jnccn.2022.7008

Table 2.

Pathological outcomes of patients who underwent a resection in the matched cohort.

	Matched cohort
	Overall	No radiotherapy	Radiotherapy	P-value
	n = 192	n = 109	n = 83
Tumor size, mm (median [IQR])	25 [18, 33]	25 [20, 30]	25 [17, 36]	0.83
T stage^a, n (%)				0.13
ypT0	8 (4.2)	2 (1.8)	6 (7.3)
ypT1-2	145 (75.9)	87 (79.8)	58 (70.7)
ypT3-4	38 (19.9)	20 (18.3)	18 (22.0)
N stage^a, n (%)				0.01^*
ypN0	88 (46.1)	41 (37.6)	47 (57.3)
ypN1	67 (35.1)	41 (37.6)	26 (31.7)
ypN2	36 (18.8)	27 (24.8)	9 (11.0)
Resection margin status^b, n (%)				0.53
R0	118 (67.0)	70 (64.8)	48 (70.6)
R1	58 (33.0)	38 (35.2)	20 (29.4)
Tumor differentiation, n (%)				0.01^*
Well (G1)	5 (2.9)	5 (5.0)	0 (0.0)
Moderate (G2)	125 (72.3)	77 (77.0)	48 (65.8)
Poor (G3)	43 (24.9)	18 (18.0)	25 (34.2)
Perineural invasion, n (%)	147 (77.4)	84 (77.8)	63 (76.8)	1
Lymphovascular invasion, n (%)	101 (53.4)	64 (59.3)	37 (45.7)	0.09
Pathologic response, n (%)				0.01^*
<5% tumor viability	28 (15.8)	8 (8.3)	20 (24.7)
≥5% tumor viability	149 (84.2)	88 (91.7)	61 (75.3)

8th edition of American Joint Committee on Cancer Staging.

1mm definition of Royal College of Pathologists.

^{* =}

significant p-value <0.05. Abbreviations: G, grade; IQR, interquartile range; n, number; yp, pathological outcome after neoadjuvant treatment. Missing data: tumor size (n=2), ypT (n=1), ypN (n=1), resection margin (n=16), tumor differentiation (n=19), perineural invasion (n=2), lymphovascular invasion (n=3), pathologic response (n=15)